Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?
Jacqueline P Williams, Carl J Johnston, Jacob N Finkelstein
https://pubmed.ncbi.nlm.nih.gov/20583979/Actively Recruiting
Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2026-04-08
72
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating whether using inhaled steroids before radiation therapy can reduce the frequency and severity of radiation pneumonitis in patients with locally advanced or metastatic non-small cell lung cancer NSCLC who are receiving chemotherapy plus radiotherapy or targeted therapy plus radiotherapy. The study focuses on whether inhaled steroids affect lung inflammation and change the response to radiation treatment. This is a randomized Phase 2 clinical trial sponsored by Instituto Nacional de Cancerologia de Mexico. Participants are assigned to receive either inhaled budesonide at 400 mcg twice daily with a spacer chamber or no additional medication, alongside their standard chemotherapy or targeted therapy combined with radiotherapy. Treatment with budesonide starts after the first radiation session and continues until pneumonitis occurs or up to 12 months. Devices containing the medication are provided monthly, and patients keep a log of their inhaler use to track adherence. During the study, participants undergo baseline assessments including medical history, lung function tests, and multiple quality of life and respiratory symptom questionnaires. Blood samples are collected before radiation and every six weeks for up to 48 weeks to measure inflammation markers. Follow-up evaluations of lung function, respiratory symptoms, side effects, and quality of life continue at 6, 12, 24, and 48 weeks after treatment. Pneumonitis severity is monitored for one year from the start of radiation therapy to assess the studys primary outcomes.
CONDITIONS
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
O
Oscar Arrieta, MD MSc
D
Diana Flores
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Instituto Nacional de Cancerologia de Mexico
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 12 months or until pneumonitis development
Participants receive chemotherapy or targeted therapy combined with radiotherapy. Those in the experimental group use inhaled budesonide twice daily starting after the first radiotherapy dose and continue until pneumonitis develops or for up to 12 months.
Monthly visits for inhaled medication device provision and adherence support; additional visits for radiotherapy and chemotherapy as per routine care
Duration - Up to 48 weeks post-radiotherapy
Participants have ongoing assessments of lung function, respiratory symptoms, quality of life, and inflammatory markers for up to 48 weeks after radiotherapy to monitor for pneumonitis and other outcomes.
Visits at 6, 12, 24, and 48 weeks post-treatment for questionnaires, lung function tests, and blood sample collection
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Jacqueline P Williams, Carl J Johnston, Jacob N Finkelstein
https://pubmed.ncbi.nlm.nih.gov/20583979/Robert Timmerman, Ronald McGarry, Constantin Yiannoutsos...
https://pubmed.ncbi.nlm.nih.gov/17050868/A Vallard, C Rancoule, H Le Floch...
https://pubmed.ncbi.nlm.nih.gov/28596060/C Henkenberens, S Janssen, M Lavae-Mokhtari...
https://pubmed.ncbi.nlm.nih.gov/26830686/Peter T Daley-Yates
https://pubmed.ncbi.nlm.nih.gov/25808113/Chet Leach, Gene L Colice, Allan Luskin
https://pubmed.ncbi.nlm.nih.gov/19962042/Nian-Hua Ding, Jian Jian Li, Lun-Quan Sun
https://pubmed.ncbi.nlm.nih.gov/23909719/Charles B Simone
https://pubmed.ncbi.nlm.nih.gov/28865520/Trevor J Bledsoe, Sameer K Nath, Roy H Decker
https://pubmed.ncbi.nlm.nih.gov/28477633/Oscar Arrieta, Enrique Guzmán-de Alba, Luis Felipe Alba-López...
https://pubmed.ncbi.nlm.nih.gov/24459776/Instituto Nacional de Cancerologia de Mexico
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Collaborating Sponsor